Several analysts have recently updated their ratings and price targets for Intellia Therapeutics (NASDAQ: NTLA):
9/9/2026 – Intellia Therapeutics had its “market outperform” rating reaffirmed by Citizens Jmp. They now have a $30.00 price target on the stock. 9/9/2026 – Intellia Therapeutics had its price target raised by Wedbush from $12.00 to $13.00. They now have a “neutral” rating on the stock. 9/9/2026 – Intellia Therapeutics had its “buy” rating reaffirmed by HC Wainwright. They now have a $25.00 price target on the stock. 8/25/2026 – Intellia Therapeutics had its “market outperform” rating reaffirmed by Citigroup Inc.. 8/25/2026 – Intellia Therapeutics had its “market outperform” rating reaffirmed by Citizens Jmp. They now have a $30.00 price target on the stock. 8/8/2026 – Intellia Therapeutics was downgraded by Wall Street Zen from “sell” to “strong sell”. 8/7/2026 – Intellia Therapeutics was upgraded by Evercore Inc from “hold” to “outperform”. They now have a $24.00 price target on the stock. 7/17/2026 – Intellia Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings . Insider Buying and Selling at Intellia Therapeutics In related news, CAO Michael Dube sold ...